NCT01652118

Brief Summary

The purpose of this study is to determine of clarithromycin effect on developing of bronchopulmonary dysplasia in preterm babies.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Oct 2011

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2011

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

July 22, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 27, 2012

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
Last Updated

July 27, 2012

Status Verified

July 1, 2012

Enrollment Period

1.2 years

First QC Date

July 22, 2012

Last Update Submit

July 26, 2012

Conditions

Keywords

bronchopulmonary dysplasiaclarithromycinpreterm babies

Outcome Measures

Primary Outcomes (1)

  • Bronchopulmonary dysplasia

    On the 28. day of birth, The investigator will determine the baby whether has developed bronchopulmonary dysplasia

    28. day of birth

Secondary Outcomes (1)

  • Overall survival

    Participants will be followed for the duration of hospital stay, an expected average of postnatal 40 weeks

Study Arms (2)

Clarithromycin

ACTIVE COMPARATOR

Fist group treated with clarithromycin which is include 10 days application.

Drug: clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia

placebo

PLACEBO COMPARATOR

Second group treated with salin as same as amount of clarithromycine volume

Drug: Saline

Interventions

SalineDRUG
placebo

Eligibility Criteria

Age1 Hour - 2 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • all infant must be under 1250 gram birth weight

You may not qualify if:

  • Major congenital anomaly,
  • CardiaC abnormality,
  • without inform consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zekai Tahir Burak Maternity Teaching Hospital

Ankara, Middle Anatolia, 06600, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Bronchopulmonary Dysplasia

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

Ventilator-Induced Lung InjuryLung InjuryLung DiseasesRespiratory Tract DiseasesInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Ugur Dilmen, Prof. Dr.

    Zekai Tahir Burak Women's Health Research and Education Hospital

    STUDY DIRECTOR

Central Study Contacts

Sadık Yurttutan, M.D

CONTACT

Fuat Emre Canpolat, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Fellowship of neonatology

Study Record Dates

First Submitted

July 22, 2012

First Posted

July 27, 2012

Study Start

October 1, 2011

Primary Completion

December 1, 2012

Study Completion

January 1, 2013

Last Updated

July 27, 2012

Record last verified: 2012-07

Locations